What was studied?
MMPOWER-3 randomized 218 participants with genetically confirmed primary mitochondrial myopathy to elamipretide or placebo for 24 weeks.
What did the researchers report?
The study did not show an improvement over placebo in its primary endpoints: six-minute walking distance and total fatigue score. Most adverse events were mild or moderate.
What are the limits?
Tolerability is not the same as demonstrated efficacy. These findings concern this disease population and study design; they do not establish benefits for healthy aging, athletic performance or other untested uses.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.